Insulin has remained the primary treatment for type 1 diabetes for over a century, but a new therapeutic approach is now being implemented through the National Health Service that offers the potential to postpone the development of the disease by several years. Concurrent with this treatment rollout, screening initiatives are expanding to identify individuals who may benefit from the intervention.
The new medication being introduced is teplizumab, which has been tested in clinical trials. One participant, a young person named Dima and his mother Elena, shared their experience of receiving a positive test indicating increased risk of developing type 1 diabetes and their involvement in the drug trial. According to medical experts including Parth Narendran, a professor of diabetes medicine at the University of Birmingham, and Dr Renuka Dias, a consultant paediatric endocrinologist at Birmingham Women’s and Children’s Hospital, these developments represent significant changes in how the condition is being managed.
The program reflects what some in the medical field view as the beginning of a new phase in type 1 diabetes care, shifting from purely managing the disease after onset to potentially preventing or delaying its appearance in at-risk populations. The combination of earlier identification through screening and access to preventative treatment options marks a notable shift in clinical practice within the NHS.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI